You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 歌禮制藥-B漲11% 向美國FDA遞交口服抗病毒藥物ASC10的猴痘適應症新藥臨牀試驗申請
格隆匯 10-27 14:10
格隆匯10月27日丨歌禮制藥-B(1672.HK)漲11.16%,報2.69港元,總市值29億港元。歌禮制藥26日在港交所公吿,已向美國食品藥品監督管理局(FDA)遞交針對猴痘病毒聚合酶的口服抑制劑候選藥物ASC10的新藥臨牀試驗(IND)申請。臨牀前研究顯示,ASC10對猴痘病毒和新型冠狀病毒具有強效抗病毒活性。ASC10擁有兩項適應症:猴痘病毒以及新型冠狀病毒感染。2022年8月,美國食品藥品監督管理局(FDA)已批准ASC10新冠感染適應症新藥臨牀試驗申請(IND),目前該項在新冠患者中開展的Ib期臨牀試驗正在美國有序進行。在美國遞交ASC10猴痘適應症新藥臨牀試驗申請將進一步拓寬歌禮病毒性疾病管線佈局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account